Lars Viktrup Selected Research

tanezumab

4/2022	Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study.
3/2022	Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis.
2/2022	Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis.
1/2022	WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee.
1/2022	Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
1/2022	General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials.
1/2022	Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera.
12/2021	Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis.
12/2021	Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.
1/2021	Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lars Viktrup Research Topics

Disease

32	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2019 - 10/2008
31	Lower Urinary Tract Symptoms 01/2019 - 10/2008
18	Osteoarthritis 03/2022 - 01/2019
16	Pain (Aches) 01/2022 - 10/2018
16	Erectile Dysfunction 01/2019 - 10/2008
9	Stress Urinary Incontinence 02/2010 - 01/2004
6	Hip Osteoarthritis (Coxarthrosis) 03/2022 - 01/2019
5	Major Depressive Disorder (Major Depressive Disorders) 01/2007 - 01/2004
4	Low Back Pain (Lumbago) 04/2022 - 10/2019
4	Knee Osteoarthritis 01/2022 - 01/2020
3	Chronic Pain 01/2022 - 10/2019
3	Arthralgia (Joint Pain) 01/2021 - 01/2019
3	Urinary Incontinence 06/2008 - 01/2005
2	Neuralgia (Stump Neuralgia) 01/2007 - 11/2005
1	Radiculopathy (Radiculopathy, Cervical) 03/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 03/2022
1	Polyneuropathies (Polyneuropathy) 03/2022
1	Mononeuropathies (Mononeuritis Multiplex) 03/2022
1	Hypesthesia (Numbness) 01/2022
1	Paresthesia (Dysesthesia) 01/2022
1	Bradycardia 01/2022
1	Orthostatic Hypotension (Postural Hypotension) 01/2022
1	Nocturia 10/2014
1	Polyuria 10/2014
1	Hypertension (High Blood Pressure) 09/2013
1	Cardiovascular Diseases (Cardiovascular Disease) 09/2013
1	Back Pain (Backache) 11/2011
1	Headache (Headaches) 11/2011
1	Ischemia 03/2011
1	Hyperhidrosis 06/2008
1	Fatigue 06/2008
1	Constipation 06/2008
1	Lung Diseases (Lung Disease) 07/2007
1	Obesity 07/2007
1	Diabetes Mellitus 07/2007
1	Fibromyalgia (Fibrositis) 01/2007
1	Anxiety Disorders (Anxiety Disorder) 01/2007
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2004
1	Mania (Manias) 01/2004
1	Urinary Retention 01/2004

Drug/Important Bio-Agent (IBA)

32	Tadalafil (Cialis)FDA Link 01/2019 - 10/2008
17	tanezumabIBA 04/2022 - 10/2018
10	Duloxetine Hydrochloride (Cymbalta)FDA Link 02/2010 - 01/2004
8	Phosphodiesterase 5 InhibitorsIBA 10/2015 - 10/2008
7	Nerve Growth Factor (NGF)IBA 01/2022 - 10/2018
5	Prostaglandins AIBA 01/2022 - 01/2019
5	Analgesics (Analgesic Drugs)IBA 11/2021 - 01/2019
5	Tamsulosin (Flomax)FDA LinkGeneric 01/2019 - 09/2011
4	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 03/2022 - 01/2020
4	Norepinephrine (Noradrenaline)FDA LinkGeneric 11/2005 - 01/2004
4	Serotonin (5 Hydroxytryptamine)IBA 11/2005 - 01/2004
3	Finasteride (Propecia)FDA LinkGeneric 06/2015 - 03/2014
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2004
2	Opioid Analgesics (Opioids)IBA 11/2021 - 01/2020
2	Acetaminophen (Paracetamol)FDA LinkGeneric 11/2021 - 01/2020
2	AntibodiesIBA 11/2021 - 10/2019
2	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 10/2015 - 09/2013
1	Celecoxib (Celebrex)FDA Link 04/2022
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 03/2011
1	Phosphotransferases (Kinase)IBA 03/2011
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2011
1	Antidepressive Agents (Antidepressants)IBA 01/2004

Therapy/Procedure

8	Therapeutics 07/2021 - 02/2010
2	Drug Therapy (Chemotherapy) 07/2021 - 01/2004
2	Replacement Arthroplasty 01/2021 - 01/2019
1	Combined Modality Therapy 01/2020
1	Institutionalization (Institutionalized Persons) 01/2005